RAN GTPase is an effector of the invasive/metastatic phenotype induced by osteopontin

Oncogene

Volumn 27, Issue 57, 2008, Pages 7139-7149

  Kurisetty, V V ^a   Johnston, P G ^a   Johnston, N ^a   Erwin, P ^a   Crowe, P ^a   Fernig, D G ^b   Campbell, F C ^a   Anderson, I P ^b   Rudland, P S ^b   El Tanani, M K ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Breast cancer invasion and metastasis; Osteopontin; RAN

Indexed keywords

OSTEOPONTIN; RAN PROTEIN; SMALL INTERFERING RNA; STAT1 PROTEIN;

ARTICLE; BREAST CANCER; CANCER INVASION; CARCINOGENICITY; CELL PROLIFERATION; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; BLOTTING, NORTHERN; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; MAMMARY NEOPLASMS, EXPERIMENTAL; NEOPLASM INVASIVENESS; OSTEOPONTIN; PHENOTYPE; PROTO-ONCOGENE PROTEINS C-MET; RAN GTP-BINDING PROTEIN; RATS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSFECTION;

RATTUS;

EID: 57349130560     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2008.325     Document Type: Article

References (51)

1. Abe H, Kamai T, Shirataki H, Oyama T, Arai K, Yoshida K. (2008). High expression of Ran GTPase is associated with local invasion and metastasis of human clear cell renal cell carcinoma. Int J Cancer 122: 2391-2397.
2. Azuma K, Sasada T, Takedatsu H, Shomura H, Koga M, Maeda Y et al. (2004). Ran, a small GTPase gene, encodes cytotoxic T lymphocyte (CTL) epitopes capable of inducing HLA-A33-restricted and tumor-reactive CTLs in cancer patients. Clin Cancer Res 10: 6695-6702.
3. Berns K, Hijmans EM, Mullenders J, Brummelkamp TR, Velds A, Heimerikx M et al. (2004). Alarge-sca le RNAi screen in human cells identifies new components of the p53 pathway. Nature 428: 431-437.
4. Beviglia L, Matsumoto K, Lin CS, Ziober BL, Kramer RH. (1997). Expression of the c-Met/HGF receptor in human breast carcinoma: correlation with tumor progression. Int J Cancer 74: 301-309.
5. Bischoff FR, Klebe C, Kretschmer J, Wittinghofer A, Ponstingl H. (1994). RanGAP1 induces GTPase activity of nuclear Ras-related Ran. Proc Natl Acad Sci USA 91: 2587-2591.
6. Bramwell VH, Doig GS, Tuck AB, Wilson SM, Tonkin KS, Tomiak A et al. (2006). Serial plasma osteopontin levels have prognostic value in metastatic breast cancer. Clin Cancer Res 12: 3337-3343.
7. Carey KL, Richards SA, Lounsbury KM, Macara IG. (1996). Evidence using a green fluorescent protein-glucocorticoid receptor chimera that the Ran/TC4 GTPase mediates an essential function independent of nuclear protein import. J Cell Biol 133: 985-996.
8. Chen H, Ke Y, Oates AJ, Barraclough R, Rudland PS. (1997). Isolation of and effector for metastasis-inducing DNAs from a human metastatic carcinoma cell line. Oncogene 14: 1581-1588.
9. Darzynkiewicz Z, Juan G, Bedner E. (2001). Determining cell cycle stages by flow cytometry. Curr Protoc Cell Biol, Chapter 8, Unit 8 4.
10. Das R, Philip S, Mahabeleshwar GH, Bulbule A, Kundu GC, Rangaswami H et al. (2005). Osteopontin: it's role in regulation of cell motility and nuclear factor kappa B-mediated urokinase type plasminogen activator expression. IUBMB Life 57: 441-447.
11. Davies BR, Davies MP, Gibbs FE, Barraclough R, Rudland PS. (1993). Induction of the metastatic phenotype by transfection of a benign rat mammary epithelial cell line with the gene for p9Ka, a rat calcium-binding protein, but not with the oncogene EJ-ras-1. Oncogene 8: 999-1008.
12. Denti S, Sirri A, Cheli A, Rogge L, Innamorati G, Putignano S et al. (2004). RanBPM is a phosphoprotein that associates with the plasma membrane and interacts with the integrin LFA-1. J Biol Chem 279: 13027-13034.
13. Dunnington DJ, Hughes CM, Monaghan P, Rudland PS. (1983). Phenotypic instability of rat mammary tumor epithelial cells. J Natl Cancer Inst 71: 1227-1240.
14. El-Tanani M, Barraclough R, Wilkinson MC, Rudland PS. (2001). Metastasis-inducing DNAregulates the expression of the osteopontin gene by binding the transcription factor Tcf-4. Cancer Res 61: 5619-5629.
15. El-Tanani M, Platt-Higgins A, Rudland PS, Campbell FC. (2004). Ets gene PEA3 cooperates with β-catenin-Lef-1 and c-Jun in regulation of osteopontin transcription. J Biol Chem 279: 20794-20806.
16. El-Tanani MK, Campbell FC, Crowe P, Erwin P, Harkin DP, Pharoah P et al. (2006a). BRCA1 suppresses osteopontin-mediated breast cancer. J Biol Chem 281: 26587-26601.
17. El-Tanani MK, Campbell FC, Kurisetty V, Jin D, McCann M, Rudland PS. (2006b). The regulation and role of osteopontin in malignant transformation and cancer. Cytokine Growth Factor Rev 17: 463-474.
18. Emberley ED, Gietz RD, Campbell JD, HayGlass KT, Murphy LC, Watson PH. (2002). RanBPM interacts with psoriasin in vitro and their expression correlates with specific clinical features in vivo in breast cancer. BMC Cancer 2: 28.
19. Furger KA, Allan AL, Wilson SM, Hota C, Vantyghem SA, Postenka CO et al. (2003). b(3) Integrin expression increases breast carcinoma cell responsiveness to the malignancy-enhancing effects of osteopontin. Mol Cancer Res 1: 810-819.
20. Hafizi S, Gustafsson A, Stenhoff J, Dahlback B. (2005). The RAN-binding protein RanBPM interacts with Axl and Sky receptor tyrosine kinases. Int J Biochem Cell Biol 37: 2344-2356.
21. Hara S, Nakashiro K, Goda H, Hamakawa H. (2008). Role of Akt isoforms in HGF-induced invasive growth of human salivary gland cancer cells. Biochem Biophys Res Commun 370: 123-128.
22. Johnston NI, Gunasekharan VK, Ravindranath A, O'Connell C, Johnston PG, El-Tanani MK. (2008). Osteopontin as a target for cancer therapy. Front Biosci 13: 4361-4372.
23. Kilty IC, Barraclough R, Schmidt G, Rudland PS. (1999). Isolation of a potential neural stem cell line from the internal capsule of an adult transgenic rat brain. J Neurochem 73: 1859-1870.
24. Kurisetty VV, Johnston PG, Rudland PS, El-Tanani MK. (2008). Identification of genes differentially expressed between benign and osteopontin transformed rat mammary epithelial cells. BMC Research Notes; accepted for publication.
25. Lounsbury KM, Richards SA, Carey KL, Macara IG. (1996). Mutations within the Ran/TC4 GTPase. Effects on regulatory factor interactions and subcellular localization. J Biol Chem 271: 32834-32841.
26. Margalit DN, Romberg L, Mets RB, Hebert AM, Mitchison TJ, Kirschner MW et al. (2004). Targeting cell division: small-molecule inhibitors of FtsZ GTPase perturb cytokinetic ring assembly and induce bacterial lethality. Proc Natl Acad Sci USA 101: 11821-11826.
27. Maulik G, Shrikhande A, Kijima T, Ma PC, Morrison PT, Salgia R. (2002). Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev 13: 41-59.
28. Morgan-Lappe SE, Tucker LA, Huang X, Zhang Q, Sarthy AV, Zakula D et al. (2007). Identification of Ras-related nuclear protein, targeting protein for xenopus kinesin-like protein 2, and stearoyl-CoA desaturase 1 as promising cancer targets from an RNAi-based screen. Cancer Res 67: 4390-4398.
29. Moye VE, Barraclough R, West C, Rudland PS. (2004). Osteopontin expression correlates with adhesive and metastatic potential in metastasis-inducing DNA-transfected rat mammary cell lines. Br J Cancer 90: 1796-1802.
30. Nishitani H, Hirose E, Uchimura Y, Nakamura M, Umeda M, Nishii K et al. (2001). Full-sized RanBPM cDNAe ncodes a protein possessing a long stretch of proline and glutamine within the N-terminal region, comprising a large protein complex. Gene 272: 25-33.
31. Oates AJ, Barraclough R, Rudland PS. (1996). The identification of osteopontin as a metastasis-related gene product in a rodent mammary tumour model. Oncogene 13: 97-104.
32. Ouellet V, Guyot MC, Le Page C, Filali-Mouhim A, Lussier C, Tonin PN et al. (2006). Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer. Int J Cancer 119: 599-607.
33. Peruzzi B, Bottaro DP. (2006). Targeting the c-Met signaling pathway in cancer. Clin Cancer Res 12: 3657-3660.
34. Pisani P, Parkin DM, Bray F, Ferlay J. (1999). Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 83: 18-29.
35. Rudland PS, Platt-Higgins A, El-Tanani M, de Silva Rudland S, Barraclough R, Winstanley JH et al. (2002). Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res 62: 3417-3427.
36. Sakata H, Stahl SJ, Taylor WG, Rosenberg JM, Sakaguchi K, Wingfield PT et al. (1997). Heparin binding and oligomerization of hepatocyte growth factor/scatter factor isoforms. Heparan sulfate glycosaminoglycan requirement for Met binding and signaling. J Biol Chem 272: 9457-9463.
37. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. (2005). Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098-1101.
38. Sazer S, Dasso M. (2000). The ran decathlon: multiple roles of Ran. J Cell Sci 113(Pt 7): 1111-1118.
39. Shinohara ML, Kim HJ, Kim JH, Garcia VA, Cantor H. (2008). Alternative translation of osteopontin generates intracellular and secreted isoforms that mediate distinct biological activities in dendritic cells. Proc Natl Acad Sci U S A 105: 7235-7239.
40. Shukla S, Maclennan GT, Hartman DJ, Fu P, Resnick MI, Gupta S. (2007). Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion. Int J Cancer 121: 1424-1432.
41. Singhal H, Bautista DS, Tonkin KS, O'Malley FP, Tuck AB, Chambers AF et al. (1997). Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res 3: 605-611.
42. Su L, Mukherjee AB, Mukherjee BB. (1995). Expression of antisense osteopontin RNAi nhibits tumor promoter-induced neoplastic transformation of mouse JB6 epidermal cells. Oncogene 10: 2163-2169.
43. Tuck AB, Chambers AF, Allan AL. (2007). Osteopontin over-expression in breast cancer: knowledge gained and possible implications for clinical management. J Cell Biochem 102: 859-868.
44. Tuck AB, Elliott BE, Hota C, Tremblay E, Chambers AF. (2000). Osteopontin-induced, integrin-dependent migration of human mammary epithelial cells involves activation of the hepatocyte growth factor receptor (Met). J Cell Biochem 78: 465-475.
45. Tuck AB, Hota C, Wilson SM, Chambers AF. (2003). Osteopontin-induced migration of human mammary epithelial cells involves activation of EGF receptor and multiple signal transduction pathways. Oncogene 22: 1198-1205.
46. Tuck AB, O'Malley FP, Singhal H, Harris JF, Tonkin KS, Kerkvliet N et al. (1998). Osteopontin expression in a group of lymph node negative breast cancer patients. Int J Cancer 79: 502-508.
47. Ue T, Yokozaki H, Kitadai Y, Yamamoto S, Yasui W, Ishikawa T et al. (1998). Co-expression of osteopontin and CD44v9 in gastric cancer. Int J Cancer 79: 127-132.
48. Wang D, Li Z, Messing EM, Wu G. (2002). Activation of Ras/Erk pathway by a novel MET-interacting protein RanBPM. J Biol Chem 277: 36216-36222.
49. Wang G, Platt-Higgins A, Carroll J, de Silva Rudland S, Winstanley J, Barraclough R et al. (2006). Induction of metastasis by S100P in a rat mammary model and its association with poor survival of breast cancer patients. Cancer Res 66: 1199-1207.
50. Wennerberg K, Rossman KL, Der CJ. (2005). The Ras superfamily at a glance. J Cell Sci 118: 843-846.
51. Yuan Y, Fu C, Chen H, Wang X, Deng W, Huang BR. (2006). The RAN-binding protein RanBPM interacts with TrkA receptor. Neurosci Lett 407: 26-31.